Author

Wunna Swe

Observed names: W. Swe, Wunna Swe (17952266)

Institution: Nuvalent, Inc. (United States)

Observed institutions: Huddersfield Royal Infirmary, Calderdale and Huddersfield NHS Foundation Trust, Nuvalent, Inc. (United States)

OpenAlex ID: A5008602020

Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study

2023 · Ann Tivey, Rohan Shotton, et al. · Blood Advances · 21

1253O Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours

2024 · A.E. Drilon, J.J. Lin, et al. · Annals of Oncology · 20

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

2018 · Allison Gathany, Robyn M. Scherber, et al. · Blood · 1

972P Neladalkib (NVL-655) efficacy and safety in patients with ALK-positive solid tumors in the ALKOVE-1 study

2025 · B.J. Solomon, A. Drilon, et al. · Annals of Oncology

P1141: Ibrutinib and Rituximab as First Line Therapy for Mantle Cell Lymphoma: a Multicentre, Real-world Uk Study

2022 · A. Tivey, R. Shotton, et al. · HemaSphere

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Interim Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

2016 · Allison H Scotch, Robyn M. Scherber, et al. · Blood

Works count: 7

Citation count: 42

H-index: 2

I10-index: 2